Search
Kairos Pharma Ltd
KAPAAdd to Watchlist
1.730USD
-0.050-2.81%
Close 09-23 16:00（ET）
37.04MMarket Cap
LossP/E TTM
Kairos Pharma Ltd (KAPA) Stock Price Target & Forecast
Analyst Rating
Based on 2 analysts giving stock ratings to Kairos Pharma Ltd in the past month.
Buy
0 Strong Buy
2 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
49.000USD+2652.81%
KAPA Analyst Recommendation Trends
In the current month, KAPA has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. KAPA average Analyst price target in the last month is 49.000.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
0
0
0
0
0
0
0
0
2
2
3
3
3
3
3
3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
2
3
3
3
3
3
3
KAPA Analyst Rating for Peer Comparison
Updated: Sep 23, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, KAPA EPS is projected to reach -0.560 in FY2026Q3, following reported EPS of -0.454 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.37
-0.53
-0.56
-0.56
-0.63
Actual
-0.07
-0.08
-0.45
--
--
Surprise
+82.46%
+85.01%
+19.00%
--
--
FAQs
What is Kairos Pharma Ltd's price target?
Analysts forecast that Kairos Pharma Ltd's price target is USD 49.00, with the highest forecast at USD 84.00 and the lowest forecast at USD 14.00.
How have Kairos Pharma LtdKAPA's recent earnings per share performed?
The market expectation was USD -0.45, while Kairos Pharma LtdKAPA's earnings per share (EPS) for the previous quarter was USD -0.08. EPS for the next quarter is expected at USD -0.56.
What is the analyst rating for Kairos Pharma Ltd?
Based on the ratings of Kairos Pharma Ltd's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.